I. MODIFIED AGREEMENTS | |||
Company* |
Company* |
Change from original agreement |
Terms/Details (Date) |
Celgene |
Pharmion Corp. (PHRM) |
Amended deal gives Pharmion additional thalidomide rights in Asia, and extends R&D deal from 2005 to 2007 |
Pharmion is making a one-time $77M payment, and will see its supply and royalty rate reduced from 36% to 23.5% of sales; Pharmion also is paying $3M for the additional Asian territories and $8M to support the collaboration (12/3) |
Genelabs |
Affymetrix Inc. (AFFX) |
They amended license to Genelabs' Linker-Aided DNA Amplification technology |
Affymetrix paid $1.25M for a fully paid up nonexclusive license that eliminates royalties and fees payable under the original December 2002 agreement (12/30) |
Mergen Ltd.* |
Oxford Gene Technology Ltd.* (UK) |
Agreement resolving patent infringement litigation between the companies |
Mergen has obtained a license from OGT for its expression chips in the U.S., Europe and Japan, allowing it to make and sell microarrays (1/20) |
XOMA Ltd. |
Genentech Inc. (NYSE:DNA) |
They restructured terms of their deal covering Raptiva, which is approved for treating plaque psoriasis |
XOMA opted to take a mid-single-digit royalty on sales, and won't be responsible for funding any development or marketing activities; XOMA no longer is obliged to repay a $40M development loan (1/12) |
II. TERMINATED AGREEMENTS | |||
Generex |
Charmed Capital plc |
They ended a proposed deal for the marketing of Generex diabetes products in India, China and Australia |
The deal would have included a $6M investment from Charmed Capital; Generex said it will seek partnerships with pharmaceutical companies instead (11/26) |
| | |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
NYSE = New York Stock Exchange. | |||
